Novartis Launches Japan Compliance Advisory Board In Wake Of Diovan Turmoil
This article was originally published in PharmAsia News
Novartis Pharma in Japan established a compliance advisory board as part of a move to salvage its tarnished image with ongoing Diovan scandals.
You may also be interested in...
The Japanese government has decided to revise its drug pricing policies starting in April 2014. Changes include extending a price premium program for two more years, bundling the pricing of similar generic drugs, and reduced pricing on long-listed drugs.
New rules separate medical devices from pharma regulations to provide clarity and regulatory efficiency, removing approval hurdles for devices and software in 2014.
PMDA's project for developing a medical information database infrastructure for 10 million people aims to better understand the probability for adverse effects with drugs and will enter its test period starting next year.